HC Wainwright Predicts AC Immune FY2026 Earnings

by · The Cerbat Gem

AC Immune (NASDAQ:ACIU – Free Report) – Analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of AC Immune in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($0.54) per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for AC Immune’s Q4 2026 earnings at ($0.23) EPS, FY2027 earnings at $0.43 EPS, FY2028 earnings at $1.15 EPS, FY2029 earnings at $1.65 EPS and FY2030 earnings at $1.73 EPS.

AC Immune (NASDAQ:ACIU – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $3.88 million during the quarter, compared to analysts’ expectations of $1.62 million. AC Immune had a negative net margin of 181.38% and a negative return on equity of 97.79%.

A number of other research analysts also recently commented on the stock. Zacks Research downgraded shares of AC Immune from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 28th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of AC Immune in a report on Wednesday, September 23rd. Finally, Weiss Ratings upgraded shares of AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, AC Immune has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Get Our Latest Report on AC Immune

AC Immune Stock Up 9.4%

NASDAQ ACIU opened at $2.44 on Monday. The firm’s fifty day moving average price is $2.54 and its two-hundred day moving average price is $2.69. AC Immune has a 1 year low of $2.02 and a 1 year high of $3.90.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AXQ Capital LP bought a new position in AC Immune during the 2nd quarter worth $25,000. Dimensional Fund Advisors LP boosted its position in shares of AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after acquiring an additional 176,701 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the period. 51.36% of the stock is owned by institutional investors.

About AC Immune

(Get Free Report)

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.

See Also